ARDX Stock Overview
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
+ 2 more risks
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.65|
|52 Week High||US$8.25|
|52 Week Low||US$0.58|
|1 Month Change||-12.48%|
|3 Month Change||-5.74%|
|1 Year Change||-90.60%|
|3 Year Change||-76.75%|
|5 Year Change||-85.80%|
|Change since IPO||-95.37%|
Recent News & Updates
|ARDX||US Biotechs||US Market|
Return vs Industry: ARDX underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: ARDX underperformed the US Market which returned -12.9% over the past year.
|ARDX Average Weekly Movement||16.5%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ARDX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: ARDX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.
Ardelyx Fundamentals Summary
|ARDX fundamental statistics|
Is ARDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ARDX income statement (TTM)|
|Cost of Revenue||-US$7.40m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.06|
|Net Profit Margin||-3,843.36%|
How did ARDX perform over the long term?See historical performance and comparison
Is Ardelyx undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ARDX ($0.65) is trading below our estimate of fair value ($31.01)
Significantly Below Fair Value: ARDX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ARDX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ARDX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARDX's PB Ratio (1.5x) is in line with the US Biotechs industry average.
How is Ardelyx forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARDX's revenue (54% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: ARDX's revenue (54% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARDX is forecast to be unprofitable in 3 years.
How has Ardelyx performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARDX is currently unprofitable.
Growing Profit Margin: ARDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARDX is unprofitable, and losses have increased over the past 5 years at a rate of 11.3% per year.
Accelerating Growth: Unable to compare ARDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: ARDX has a negative Return on Equity (-238.48%), as it is currently unprofitable.
How is Ardelyx's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ARDX's short term assets ($114.2M) exceed its short term liabilities ($47.8M).
Long Term Liabilities: ARDX's short term assets ($114.2M) exceed its long term liabilities ($17.4M).
Debt to Equity History and Analysis
Debt Level: ARDX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ARDX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARDX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ARDX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 7.3% each year.
What is Ardelyx current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARDX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ARDX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Raab (56 yo)
Mr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He is a Director of Tempest Therapeutics Inc. since May 2019 and its Chairman...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD4.23M) is above average for companies of similar size in the US market ($USD771.12K).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
Experienced Management: ARDX's management team is considered experienced (2 years average tenure).
Experienced Board: ARDX's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ARDX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.5%.
Ardelyx, Inc.'s employee growth, exchange listings and data sources
- Name: Ardelyx, Inc.
- Ticker: ARDX
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$94.452m
- Shares outstanding: 144.60m
- Website: https://www.ardelyx.com
Number of Employees
- Ardelyx, Inc.
- 400 Fifth Avenue
- Suite 210
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.